Redefining Lung Therapy Through Inhalable RNA Dry Powder Formulations

Our innovative RNA delivery platform is redefining lung therapy through spray-dried, room-temperature-stable dry powders of RNA-loaded lipid nanoparticles. Designed for deep lung deposition via inhalation, our technology enables targeted, needle-free delivery of RNA therapeutics—eliminating the need for refrigeration, injections, or complex preparation. It supports patient self-administration at home, offering a more accessible and adherence-friendly alternative to conventional treatments. The dry powder formulation overcomes key barriers such as RNA instability and inefficient delivery often seen with traditional inhalation methods. Its versatility makes it suitable for treating a range of chronic respiratory diseases with high unmet needs, including severe asthma, COPD, and idiopathic pulmonary fibrosis. By enabling efficient, localized delivery of RNA directly to the lungs, this platform has the potential to shift current treatment paradigms and significantly improve outcomes and quality of life for patients living with debilitating pulmonary conditions.